[Skip to Navigation]
Sign In
Comment & Response
June 16, 2022

Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?

Author Affiliations
  • 1Sarah Cannon Research Institute, London, United Kingdom
  • 2Breast Cancer Research Unit, Instituto Nacional de Cancer, Rio de Janeiro, Brazil
JAMA Oncol. 2022;8(8):1220-1221. doi:10.1001/jamaoncol.2022.1919

To the Editor After reading the Review by Tarantino et al1 recently published in JAMA Oncology, we became very excited to hopefully see a change in the paradigms for ERBB2-positive metastatic breast cancer (MBC) but also intrigued by some provocative suggestions.

First, to help clinicians define a population and hopefully allow inclusion in future-proof clinical trials, from the authors’ perspective, what is considered to be a long-term response? Is there a cutoff for this? Does it depend on the clinical trial inclusion criteria met by the patient?

Add or change institution